EVOTAZ (E.R. Squibb & Sons, L.L.C.)
Welcome to the PulseAid listing for the EVOTAZ drug offered from E.R. Squibb & Sons, L.L.C.. This HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],UGT1A1 Inhibitors [MoA],UDP Glucuronosyltransferases Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 3A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | E.R. Squibb & Sons, L.L.C. |
| NON-PROPRIETARY NAME: | atazanavir and cobicistat |
| SUBSTANCE NAME: | ATAZANAVIR SULFATE; COBICISTAT |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],UGT1A1 Inhibitors [MoA],UDP Glucuronosyltransferases Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 3A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2015-01-29 |
| END MARKETING DATE: | 0000-00-00 |
EVOTAZ HUMAN PRESCRIPTION DRUG Details:
| Item Description | EVOTAZ from E.R. Squibb & Sons, L.L.C. |
| LABELER NAME: | E.R. Squibb & Sons, L.L.C. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 300; 150(mg/1; mg/1) |
| START MARKETING DATE: | 2015-01-29 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0003-3641_a85ac210-0d90-457c-827b-7b7bc64681e2 |
| PRODUCT NDC: | 0003-3641 |
| APPLICATION NUMBER: | NDA206353 |
Other ATAZANAVIR SULFATE; COBICISTAT Pharmaceutical Manufacturers / Labelers:
